Opportunities to create and expand the range and responsiveness of personalised care services to patients.
COVID-19 has placed unprecedented pressure on our health system. This brings an added risk to people with long term conditions who need ongoing proactive care to stay well and avoid deterioration.
Bayer has received approval for the use of its oral Factor Xa inhibitor Xarelto® (rivaroxaban) to treat VTE and to prevent VTE recurrence in children from birth to below 18 years after at least 5 days of initial parenteral anticoagulation treatment, including catheter related thrombosis, cerebral vein and sinus thrombosis. The use of a new formulation and strength granules for oral suspension 1mg/ml was also approved.
This document is the update of an interim guidance originally published under the title “Clinical management of COVID-19: interim guidance, 27 May 2020.
Three clinical trial platforms working together to test the effects of anticoagulants in people with COVID-19 have paused enrolment of critically ill hospitalised patients.
The past year has been challenging for all of us in the NHS.
When looking at the impact of the pandemic on the field of cardiovascular disease (CVD), reduced screening opportunities and cancelled clinics and procedures have caused widespread disruption.
Draft NICE guidance on the management of atrial fibrillation has come under criticism for its recommendation around the use of apixaban or dabigatran as first choice options for anticoagulation.
A COVID-19 vaccination available before the close of 2020 has brought a glimmer of light in an exceptionally challenging and painful year of the COVID-19 pandemic.
Page 1 of 11
Next